Skip to content
Aton
EN
FR
EN
FR
Home
About Us
Our Strategy
Our Platforms
Open menu
Our Platforms
Preclinical & Clinical Services
Monoclonal Antibodies Production
Laboratory Equipment Production
Human Tissue Provision
Insights & News
Contact Us
Investors
Newsletter Signup
Press release – Annual report 2024
Half-year results 2024
General Meeting of September 30, 2024
Aton successfully completes its financial restructuring
Notice of Annual General Meeting – July 2024
Initiate discussions with creditors
Annual results 2023 – Publication postponed
Bond redemption schedule
Hybrigenics continues its development plan
2023: a year of profound change